Aptahem strengthens the company’s management team with the appointment of a new Chief Medical Officer in advance of the clinical program

2018-02-27

Aptahem AB (publ) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved in the disease process. Aptahem is today pleased to announce the appointment...

Read More

Aptahem’s scale-up process for an efficient larger-scale manufacture of Apta-1 is finalized

2018-02-20

Aptahem AB (Aktietorget: APTA) a biotechnology company which is developing aptamer-based drugs for the treatment of life-threatening conditions in which coagulation and inflammation work together in the disease process, announces that production process of the company´s drug candidate Apta-1...

Read More